Citations

Clear

1727 citation(s) found for "Fu, Alan".

Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma
DiNorcia, Joseph , Haydel, Brandy , Tabrizian, Parissa , Ruiz, Richard , Klintmalm, Göran B. , Senguttuvan, Srinath, Lee, David D. , Verna, Elizabeth C. , Halazun, Karim J. , Chapman, William C. , Vachharajani, Neeta , Aucejo, Federico , Nguyen, Mindie H. , Melcher, Marc L. , Tevar, Amit D. , Humar, Abhinav , Mobley, Constance M. , Ghobrial, R. Mark , Nydam, Trevor L. , Amundsen, Beth, Markmann, James F. , Berumen, Jennifer , Hemming, Alan W. , Langnas, Alan N. , Carney, Carol A., Sudan, Debra L. , Hong, Johnny C. , Kim, Joohyun , Zimmerman, Michael A. , Rana, Abbas , Kueht, Michael , Jones, Christopher M. , Fishbein, Thomas , Markovic, Daniela , Busuttil, Ronald W. , Taner, C. Burcin , Lee, David D , Melcher, Marc L , Halazun, Karim J , Chapman, William C , Sudan, Debra L , Florman, Sander , Hoteit, Maarouf , Levine, Matthew H , Agopian, Vatche G.

Mayo Clinic

Annals of Surgery | March 22, 2019 | Volume: 271 | Issue: 4 | Pages: 616-624

10.1097/sla.0000000000003253 | PMID 30870180 Get It

Objective: The aim of the study was to determine the rate, predictors, and impact of complete pathologic response (cPR) to pretransplant locoregional therapy (LRT) in a large, multicenter cohort of hepatocellular carcinoma (HCC) patients undergoing liver transplantation (LT). Background: LRT is used to mitigate waitlist dropout for patients with HCC awaiting LT. Degree of tumor necrosis found on explant has been associated with recurrence and overall survival, but has not been evaluated in a large, multicenter study. Methods: Comparisons were made among patients receiving pre-LT LRT with (n = 802) and without (n = 2637) cPR from the United States Multicenter HCC Transplant Consortium (UMHTC), and multivariable predictors of cPR were identified using logistic regression. Results: Of 3439 patients, 802 (23%) had cPR on explant. Compared with patients without cPR, cPR patients were younger; had lower Model for End-stage Liver Disease (MELD) scores, AFP levels, and neutrophil–lymphocyte ratios (NLR); were more likely to have tumors within Milan criteria and fewer LRT treatments; and had significantly lower 1-, 3-, and 5-year incidence of post-LT recurrence (1.3%, 3.5%, and 5.2% vs 6.2%, 13.5%, and 16.4%; P < 0.001) and superior overall survival (92%, 84%, and 75% vs 90%, 78%, and 68%; P < 0.001). Multivariable predictors of cPR included age, sex, liver disease diagnosis, MELD, AFP, NLR, radiographic Milan status, and number of LRT treatments (C-statistic 0.67). Conclusions: For LT recipients with HCC receiving pretransplant LRT, achieving cPR portends significantly lower posttransplant recurrence and superior survival. Factors predicting cPR are identified, which may help prioritize patients and guide LRT strategies to optimize posttransplant cancer outcomes.
Influence of Multimorbidity on Burden and Appropriateness of Implantable Cardioverter‐Defibrillator Therapies
Hajduk, Alexandra M. , Gurwitz, Jerry H. , Tabada, Grace H., Masoudi, Frederick A. , Magid, David J. , Greenlee, Robert T. , Sung, Sue Hee, Liu, Taylor I. , Smith, David H. , Fiocchi, Frances, Gill, Thomas M. , Gupta, Nigel, Peterson, Pamela N., Schuger, Claudio , Vidaillet, Humberto, Hammill, Stephen C., Allore, Heather , Go, Alan S. , Gill, Thomas M , Cassidy‐Bushrow, Andrea E. , Liu, Taylor , Reynolds, Kristi , Goldberg, Robert Joel , Peterson, Pamela N.

Mayo Clinic

Journal of the American Geriatrics Society | March 20, 2019 | Volume: 67 | Issue: 7 | Pages: 1370-1378

10.1111/jgs.15839 | PMID 30892695 Get It

OBJECTIVE To determine whether burden of multiple chronic conditions (MCCs) influences the risk of receiving inappropriate vs appropriate device therapies. DESIGN Retrospective cohort study. SETTING Seven US healthcare delivery systems. PARTICIPANTS Adults with left ventricular systolic dysfunction receiving an implantable cardioverter‐defibrillator (ICD) for primary prevention. MEASUREMENTS Data on 24 comorbid conditions were captured from electronic health records and categorized into quartiles of comorbidity burden (0‐3, 4‐5, 6‐7 and 8‐16). Incidence of ICD therapies (shock and antitachycardia pacing [ATP] therapies), including appropriateness, was collected for 3 years after implantation. Outcomes included time to first ICD therapy, total ICD therapy burden, and risk of inappropriate vs appropriate ICD therapy. RESULTS Among 2235 patients (mean age = 69 ± 11 years, 75% men), the median number of comorbidities was 6 (interquartile range = 4‐8), with 98% having at least two comorbidities. During a mean 2.2 years of follow‐up, 18.3% of patients experienced at least one appropriate therapy and 9.9% experienced at least one inappropriate therapy. Higher comorbidity burden was associated with an increased risk of first inappropriate therapy (adjusted hazard ratio [HR] = 1.94 [95% confidence interval {CI} = 1.14‐3.31] for 4‐5 comorbidities; HR = 2.25 [95% CI = 1.25‐4.05] for 6‐7 comorbidities; and HR = 2.91 [95% CI = 1.54‐5.50] for 8‐16 comorbidities). Participants with 8‐16 comorbidities had a higher total burden of ICD therapy (adjusted relative risk [RR] = 2.12 [95% CI = 1.43‐3.16]), a higher burden of inappropriate therapy (RR = 3.39 [95% CI = 1.67‐6.86]), and a higher risk of receiving inappropriate vs appropriate therapy (RR = 1.74 [95% CI = 1.07‐2.82]). Comorbidity burden was not significantly associated with receipt of appropriate ICD therapies. Patterns were similar when separately examining shock or ATP therapies. CONCLUSIONS In primary prevention ICD recipients, MCC burden was independently associated with an increased risk of inappropriate but not appropriate device therapies. Comorbidity burden should be considered when engaging patients in shared decision making about ICD implantation.
Conversation: Beyond black boxes: tackling artificial intelligence as a design material
Berzowska, Joanna, O'Murchu, Nora, Kelliher, Aisling , Barry, Barbara , Smeaton, Alan F.

Mayo Clinic

Proceedings of DRS | March 16, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21606/drs.2018.784 Get It

Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome
Innocenti, Federico , Qu, Xueping , Niedzwiecki, Donna , Tam, Rachel, Mahajan, Shilpi, Goldberg, Richard M. , Blanke, Charles D. , Sanoff, Hanna K. , Atkins, James N., Polite, Blasé N. , Lenz, Heinz‐Josef , Kabbarah, Omar , Zemla, Tyler J, Niedzwiecki, Donna , Ou, Fang‐Shu , Zemla, Tyler , Bertagnolli, Monica M. , Venook, Alan P. , Sanoff, Hanna

Mayo Clinic

Journal of Clinical Oncology | March 13, 2019 | Volume: 37 | Issue: 14 | Pages: 1217-1227

10.1200/jco.18.01798 | PMID 30865548 Get It

PURPOSE CALGB/SWOG 80405 was a randomized phase III trial that found no statistically significant difference in overall survival (OS) in patients with first-line metastatic colorectal cancer treated with chemotherapy plus either bevacizumab or cetuximab. Primary tumor DNA from 843 patients has been used to discover genetic markers of OS. PATIENTS AND METHODS Gene mutations were determined by polymerase chain reaction. Microsatellite status was determined by genotyping of microsatellites. Tumor mutational burden (TMB) was determined by next-generation sequencing. Cox proportional hazard models were used, with adjusting factors. Interaction of molecular alterations with either the bevacizumab or the cetuximab arms was tested. RESULTS Patients with high TMB in their tumors had longer OS than did patients with low TMB (hazard ratio [HR], 0.73 [95% CI, 0.57 to 0.95]; P = .02). In patients with microsatellite instability–high (MSI-H) tumors, longer OS was observed in the bevacizumab arm than in the cetuximab arm (HR, 0.13 [95% CI, 0.06 to 0.30]; interaction P < .001 for interaction between microsatellite status and the two arms). Patients with BRAF mutant tumors had shorter OS than did patients with wild-type (WT) tumors (HR, 2.01 [95% CI, 1.49 to 2.71]; P < .001). Patients with extended RAS mutant tumors had shorter OS than did patients with WT tumors (HR, 1.52 [95% CI, 1.26 to 1.84]; P < .001). Patients with triple-negative tumors (WT for NRAS/ KRAS/ BRAF) had a median OS of 35.9 months (95% CI, 33.0 to 38.8 months) versus 22.2 months (95% CI, 19.6 to 24.4 months ) in patients with at least one mutated gene in their tumors ( P < .001). CONCLUSION In patients with metastatic colorectal cancer treated in first line, low TMB, and BRAF and RAS mutations are negative prognostic factors. Patients with MSI-H tumors benefited more from bevacizumab than from cetuximab, and studies to confirm this effect of MSI-H are warranted.
Three-Dimensional Printed Biopatches With Conductive Ink Facilitate Cardiac Conduction When Applied to Disrupted Myocardium
Pedrotty, Dawn , Kuzmenko, Volodymyr , Sugrue, Alan , Livia, Christopher , Vaidya, Vaibhav R. , Asirvatham, Samuel J. , Gatenholm, Paul , Pedrotty, Dawn M, Sugrue, Alan M, Asirvatham, Samuel J , Livia, Christopher , Karabulut, Erdem , McLeod, Christopher J. , Kapa, Suraj

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | March 8, 2019 | Volume: 12 | Issue: 3 | Pages: No page available

10.1161/circep.118.006920 | PMID 30845835 Get It

Background: Reentrant ventricular arrhythmias are a major cause of sudden death in patients with structural heart disease. Current treatments focus on electrically homogenizing regions of scar contributing to ventricular arrhythmia with ablation or altering conductive properties using antiarrhythmic drugs. The high conductivity of carbon nanotubes may allow restoration of conduction in regions where impaired electrical conduction results in functional abnormalities. We propose a new concept for arrhythmia treatment using a stretchable, flexible biopatch with conductive properties to attempt to restore conduction across regions in which activation is disrupted. Methods: Carbon nanotube patches composed of nanofibrillated cellulose/single-walled carbon nanotube ink 3-dimensionally printed in conductive patterns onto bacterial nanocellulose were developed and evaluated for conductivity, flexibility, and mechanical properties. The patches were applied on 6 canines to epicardium before and after surgical disruption. Electroanatomic mapping was performed on normal epicardium, then repeated over surgically disrupted epicardium, and then finally with the patch applied passively. Results: We developed a 3-dimensional printable carbon nanotube ink complexed on bacterial nanocellulose that was (1) expressable through 3-dimensional printer nozzles, (2) electrically conductive, (3) flexible, and (4) stretchable. Six canines underwent thoracotomy, and, during epicardial ventricular pacing, mapping was performed. We demonstrated disruption of conduction after surgical incision in all 6 canines based on activation mapping. The patch resulted in restored conduction based on mapping and assessment of conduction direction and velocities in all canines. Conclusions: We have demonstrated 3-dimensional custom-printed electrically conductive carbon nanotube patches can be surgically manipulated to improve cardiac conduction when passively applied to surgically disrupted epicardial myocardium in canines.
Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405.
Naughton, Michelle J. , Earle, Craig C. , Höchster, Howard S. , Blanke, Charles D. , Schrag, Deborah , Dueck, Amylou C. , Niedzwiecki, Donna , Shaw, James Edward , Grothey, Axel , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 6504-6504

10.1200/jco.2015.33.15_suppl.6504 Get It

Alliance A091104: A phase II trial of MK-2206 in patients (pts) with progressive, recurrent/metastatic adenoid cystic carcinoma.
Foster, Nathan R. , Meyers, Jeffrey P., Vasudeva, Shyamprasad Deraje, Katabi, Nora , Pfister, David G. , Horvath, Laura E., Erlichman, Charles , Ho, Alan L. , Antonescu, Cristina R. , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 6039-6039

10.1200/jco.2015.33.15_suppl.6039 Get It

A molecular and clinico-pathological model for predicting abiraterone acetate/prednisone (AA/P) efficacy in metastatic castrate resistant prostate cancer (mCRPC).
Qin, Rui , Sicotte, Hugues , Carlson, Rachel E. , Tan, Winston , Jiménez, Rafael E. , Wang, Liewei , Eckel‐Passow, Jeanette E. , Costello, Brian A. , Pitot, Henry C., Dronca, Roxana , Wu, Kevin J. , Moynihan, Timothy J. , Atwell, Thomas D. , McMenomy, Brendan P., Kohli, Manish , Wang, Liguo , Quevedo, Fernando , Ho, Thai H. , Bryce, Alan H. , Dehm, Scott M.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 5056-5056

10.1200/jco.2015.33.15_suppl.5056 Get It

Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101.
Ahmad, Syed A. , Marsh, Robert , Collisson, Eric A. , Schwartz, Lawrence H., Martin, Robert C.G. , Conway, William, Truty, Mark J. , Kindler, Hedy L. , Lowy, Andrew M. , Philip, Philip Agop, Cardin, Dana B. , LoConte, Noelle K. , Cardin, Dana B , LoConte, Noelle , Katz, Matthew H. G. , Shi, Qian , Herman, Joseph M. , Bekaii‐Saab, Tanios , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4008-4008

10.1200/jco.2015.33.15_suppl.4008 Get It

Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).
Kulke, Matthew H. , Niedzwiecki, Donna , Foster, Nathan R. , Fruth, Briant, Kunz, Pamela L. , Kennecke, Hagen F. , Wolin, Edward M. , Niedzwiecki, Donna , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4005-4005

10.1200/jco.2015.33.15_suppl.4005 Get It